登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
Acupuncture Combined With PD-1/PD-L1 Inhibitors for Advanced Lung Cancer
ClinicalTrials.gov 上登记的一项肺癌开放试验,由中国中医科学院广安门医院牵头,本站收录的另外 1 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 2
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
- 牵头方中国中医科学院广安门医院Guang'anmen Hospital北京医院页面
- 研究中心安徽医科大学第一附属医院First Affiliated Hospital of Anhui Medical University合肥医院页面
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT06926140,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 7
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(7 项)收起清单
18 岁 至 75 岁;性别:不限
登记记录的入选字段
Non-small cell lung cancer AJCC lung cancer staging of stage IIIB-IV, or small cell lung cancer staging of extensive stage;
入选标准第 3 条
Those who have received acupuncture treatment or other clinical trials within 1 month prior to randomization;
排除标准第 9 条
ECOG/PS score of grade 0-1 and expected survival ≥ 3 months;
入选标准第 2 条
Non-small cell lung cancer adenocarcinoma patients do not have EGFR-sensitive mutations, ALK fusions, ROS1 fusions, BRAFV600 mutations, NTRK fusions, RET fusions, MET14 skipping mutations, and amplified gene-driven mutations by genetic testing;
入选标准第 5 条
Having at least 1 measurable tumor lesion (diameter > 1cm) or lymph node short diameter ≥ 1.5cm;
入选标准第 9 条
Those who are pregnant or breastfeeding;
排除标准第 6 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:诊断及确认方式;试验排除的其他疾病。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06926140,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Age 18-75 years; ECOG/PS score of grade 0-1 and expected survival ≥ 3 months; Non-small cell lung cancer AJCC lung cancer staging of stage IIIB-IV, or small cell lung cancer staging of extensive stage; PD-L1 immunohistochemistry detection of tumor cell positive proportion score (TPS) <50%; Non-small cell lung cancer adenocarcinoma patients do not have EGFR-sensitive mutations, ALK fusions, ROS1 fusions, BRAFV600 mutations, NTRK fusions, RET fusions, MET14 skipping mutations, and amplified gene-driven mutations by genetic testing; Patients with no previous systemic therapy/first-line treatment; Patients suitable for chemotherapy combined with immunotherapy; Traditional Chinese Medicine (TCM) diagnosis of Qi Depression; Having at least 1 measurable tumor lesion (diameter > 1cm) or lymph node short diameter ≥ 1.5cm; Sign the informed consent form and voluntarily participate in this study.排除标准:Exclusion Criteria:
Combined with other primary malignant tumors; Those who have contraindications to immunotherapy after basic assessment of immunotherapy; Those with autoimmune diseases or those who need long-term treatment with systemic steroids or immunosuppressants; Those with combined serious and uncontrolled primary diseases of heart, cerebrovascular, liver, kidney, hematopoietic system and so on; Those with metal allergy or severe fear of needles; Those who are pregnant or breastfeeding; Those who are unable to cooperate to complete the assessment due to mental disorder, intellectual or language impairment; Those with active severe infectious or inflammatory diseases; Those who have received acupuncture treatment or other clinical trials within 1 month prior to randomization; In the judgment of the investigator, persons who have a concomitant medical condition that seriously jeopardizes the safety of the participant or interferes with the completion of the study, or who are deemed to have other reasons for not being suitable for enrollment.
引自 ClinicalTrials.gov, NCT06926140, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06926140,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。